Harel becomes 'market maker'

Harel Investment House has agreed to issue "buy" and "sell" orders, increasing the negotiability of stock in Unitronics.

February 23, 2006 06:48
unitronics logo 88

unitronics logo 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Harel Investment House has agreed to issue "buy" and "sell" orders, increasing the negotiability of stock in Unitronics, a maker of industrial automation products that is listed on both the Tel Aviv Stock Exchange and the Euronext bourse in Brussels. Harel said Wednesday this was its first such agreement and that it was in contacts toward becoming a market maker for other companies as well. According to Harel CEO Gil Hod, the investment house intends to be a key player in the burgeoning field. The Knesset Finance Committee finalized legislation advanced by the Israel Securities Authority to enable market making in late 2003, allowing it to begin in March 2004.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection